Kannalife Sciences, Inc. (Kannalife), is a pharmaceutical and phyto-medical company involved in developmentof novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health Cannabinoids as Antioxidants and Neuroprotectants Kannalife is currently conducting R&D for a target drug candidate to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain. The firm is also conducting R&D on novel therapeutics to break the blood/brain barrier to be used for the treatment and prevention of oxidative and neuro-toxic stresses born from a variety of ailments and illnesses. With the objective of developing treatments to improve the quality of life of patients with neurodegenerative diseases, the firm's scientific team have background in phyto-medical, biological and pharmaceutical sciences with a long track record of successfully developing drugs from plant sources that are complex in nature and structure. Collectively, the team have published in over 300 notable journal publications and hold inventorships in over 65 patents. Our goal is to become a profitable and socially responsible company that de